{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:48:31Z","timestamp":1793760511103,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.semarthrit.2023.152314","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T11:26:01Z","timestamp":1700825161000},"page":"152314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6792-8506","authenticated-orcid":false,"given":"Lieke","family":"Scheepers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Lung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2023.152314_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152314_bib0002","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"10.1016\/j.semarthrit.2023.152314_bib0003","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus Methotrexate in Rheumatoid Arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152314_bib0004","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"Van Der Heijde","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152314_bib0005","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis","volume":"367","author":"Van Vollenhoven","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"10093","key":"10.1016\/j.semarthrit.2023.152314_bib0006","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152314_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001673","article-title":"Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b\/4 methotrexate withdrawal non-inferiority study (ORAL Shift)","volume":"7","author":"Cohen","year":"2021","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152314_bib0008","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152314_bib0009","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"issue":"9865","key":"10.1016\/j.semarthrit.2023.152314_bib0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152314_bib0011","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152314_bib0012","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152314_bib0013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"13","key":"10.1016\/j.semarthrit.2023.152314_bib0014","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in Patients with Refractory Rheumatoid Arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152314_bib0015","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator\u2013Controlled Trial","volume":"72","author":"Vollenhoven","year":"2020","journal-title":"Arthritis & Rheumatology"},{"issue":"10139","key":"10.1016\/j.semarthrit.2023.152314_bib0016","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"10188","key":"10.1016\/j.semarthrit.2023.152314_bib0017","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152314_bib0018","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III<\/scp>, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis & Rheumatology"},{"issue":"10139","key":"10.1016\/j.semarthrit.2023.152314_bib0019","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.semarthrit.2023.152314_bib0020","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152314_bib0021","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-013-2329-9","article-title":"The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"32","author":"Kawalec","year":"2013","journal-title":"Clinical Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152314_bib0022","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152314_bib0023","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Pan","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152314_bib0024","first-page":"269","article-title":"Factors affecting therapeutic compliance: A review from the patient's perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.semarthrit.2023.152314_bib0025","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/PPA.S117774","article-title":"Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach","volume":"10","author":"Alten","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152314_bib0026","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Research Notes"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152314_bib0027","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152314_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002409","article-title":"After 25 years of drug development, do we know JAK?","volume":"8","author":"Mortezavi","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2023.152314_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac068","article-title":"Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data","author":"Barbulescu","year":"2022","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152314_bib0030","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","article-title":"Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?","volume":"80","author":"Harigai","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152314_bib0031","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152314_bib0032","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:11:30Z","timestamp":1758733890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223001567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":32,"alternative-id":["S0049017223001567"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152314","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152314"}}